BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Rath T, Atreya R, Bodenschatz J, Uter W, Geppert CE, Vitali F, Fischer S, Waldner MJ, Colombel JF, Hartmann A, Neurath MF. Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial. Gastroenterology 2023;164:241-55. [PMID: 36279923 DOI: 10.1053/j.gastro.2022.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Panés J, Loftus EV, Higgins PDR, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C, Tran J, Sanchez Gonzalez Y, Vermeire S. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. Inflamm Bowel Dis 2023:izac260. [PMID: 36645051 DOI: 10.1093/ibd/izac260] [Reference Citation Analysis]
3 Mantzaris GJ. Editorial: symptoms predicting active intestinal inflammation in patients with IBD. Aliment Pharmacol Ther 2023;57:165-6. [PMID: 36480722 DOI: 10.1111/apt.17281] [Reference Citation Analysis]
4 Sudhakar P, Wellens J, Verstockt B, Ferrante M, Sabino J, Vermeire S. Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches? Gut 2023;72:192-204. [PMID: 36171081 DOI: 10.1136/gutjnl-2022-328221] [Reference Citation Analysis]
5 Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 2022;71:2587-97. [PMID: 35927032 DOI: 10.1136/gutjnl-2021-326562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV Jr, Louis E. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment Pharmacol Ther 2022. [PMID: 36266762 DOI: 10.1111/apt.17242] [Reference Citation Analysis]
7 Shapina MV. Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-90-97] [Reference Citation Analysis]
8 Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00916-8. [PMID: 36152897 DOI: 10.1016/j.cgh.2022.09.018] [Reference Citation Analysis]
9 Wang Z, Wang X, Zhao X, Hu Z, Sun D, Wu D, Xing Y. Causal relationship between bipolar disorder and inflammatory bowel disease: A bidirectional two-sample mendelian randomization study. Front Genet 2022;13:970933. [DOI: 10.3389/fgene.2022.970933] [Reference Citation Analysis]
10 Argmann C, Hou R, Ungaro RC, Irizar H, Al-Taie Z, Huang R, Kosoy R, Venkat S, Song WM, Di'Narzo AF, Losic B, Hao K, Peters L, Comella PH, Wei G, Atreja A, Mahajan M, Iuga A, Desai PT, Branigan P, Stojmirovic A, Perrigoue J, Brodmerkel C, Curran M, Friedman JR, Hart A, Lamousé-Smith E, Wehkamp J, Mehandru S, Schadt EE, Sands BE, Dubinsky MC, Colombel JF, Kasarskis A, Suárez-Fariñas M. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut 2022:gutjnl-2021-326451. [PMID: 36109152 DOI: 10.1136/gutjnl-2021-326451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2022;20:2074-82. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Biron A, Beaugerie L, Chazouillères O, Kirchgesner J. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;56:857-68. [PMID: 35789494 DOI: 10.1111/apt.17123] [Reference Citation Analysis]
13 Ferrante M, Irving PM, Selinger CP, D'Haens G, Kuehbacher T, Seidler U, Gropper S, Haeufel T, Forgia S, Danese S, Klaus J, Feagan BG; spesolimab in UC phase II clinical trial investigators. Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opin Drug Saf 2022. [PMID: 35861588 DOI: 10.1080/14740338.2022.2103536] [Reference Citation Analysis]
14 Mulberg AE, Conklin LS, Croft NM; I-ACT for Children Pediatric Extrapolation Working Group. Pediatric Extrapolation of Adult Efficacy to Children Is Critical for Efficient and Successful Drug Development. Gastroenterology 2022;163:77-83. [PMID: 35288113 DOI: 10.1053/j.gastro.2022.03.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
16 Verstockt B, Parkes M, Lee JC. How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? Gastroenterology 2022;162:1383-95. [PMID: 34995535 DOI: 10.1053/j.gastro.2021.12.245] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
17 Torres J, Ungaro RC, Colombel JF. Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We? Gastroenterology 2022;162:1452-5. [PMID: 34995527 DOI: 10.1053/j.gastro.2021.07.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Disease-modifying anti-asthmatic drugs. The Lancet 2022;399:1664-8. [DOI: 10.1016/s0140-6736(22)00331-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G, Sultan K, Lukin D, Dubinsky MC, Colombel JF; New York Crohn’s and Colitis Organization (NYCCO). Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability. Clin Gastroenterol Hepatol 2022;20:e761-9. [PMID: 34033922 DOI: 10.1016/j.cgh.2021.05.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022;162:1424-38. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
21 Crippa J, Altomare DF, Spinelli A. Cutting-Edge Research Trends in Colorectal Disease. J Clin Med 2022;11:1036. [PMID: 35207309 DOI: 10.3390/jcm11041036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
23 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2022;28:1254-64. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Sparrow MP. Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lémann Index? Gastroenterology 2021;161:800-2. [PMID: 34175282 DOI: 10.1053/j.gastro.2021.06.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Pariente B, Torres J, Burisch J, Arebi N, Barberio B, Duricova D, Ellul P, Goldis A, Kaimakliotis I, Katsanos K, Krznaric Ž, McNamara D, Pedersen N, Sebastian S, Azahaf M, Weimers P, Lung P, Lacognata C, Horak M, Christodoulou D, Domislovic V, Murphy I, Lambert J, Ungaro R, Colombel JF, Mary JY. Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. Gastroenterology 2021;161:853-864.e13. [PMID: 34052277 DOI: 10.1053/j.gastro.2021.05.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
28 Schnitzler F, Seitz T, Tillack-schreiber C, Lange S, Waggershauser C, Ochsenkühn T. Early Start of Infliximab in Crohn’s Disease Increases Rates of Endoscopic Remission and Decreases Stenosis Formation: Experiences From a Single Center Cohort. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab060] [Reference Citation Analysis]
29 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
30 Noor NM, Parkes M, Raine T. Moving towards more patient-centred clinical trials in IBD. Nat Rev Gastroenterol Hepatol 2021;18:673-4. [PMID: 34312526 DOI: 10.1038/s41575-021-00500-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]